Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy
Clinical trial NCT04691817 · RECRUITING
Trial details
- NCT number
- NCT04691817
- Sponsor
- Abramson Cancer Center at Penn Medicine
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-07-25
- Primary completion
- 2026-12-01
- Enrollment
- 28
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.